Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kevetrin in Platinum-Resistant/Refractory Ovarian Cancer
NCT03042702Phase 2Completed
- Sponsor
- Innovation Pharmaceuticals Inc.
- Start
- Feb 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of kevetrin in ovarian cancer, sponsored by Innovation Pharmaceuticals Inc.. Started Feb 2017; status: completed.
02
Drugs
kevetrin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03042702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03042702.